HighTower Advisors LLC Buys 48,052 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

HighTower Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 32.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 196,657 shares of the company's stock after purchasing an additional 48,052 shares during the period. HighTower Advisors LLC's holdings in Teva Pharmaceutical Industries were worth $4,334,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in TEVA. Smithfield Trust Co grew its position in shares of Teva Pharmaceutical Industries by 55.7% during the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter worth approximately $66,000. IFP Advisors Inc increased its stake in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock worth $88,000 after acquiring an additional 1,960 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Teva Pharmaceutical Industries in the 4th quarter valued at $104,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on TEVA shares. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.43.

Remove Ads

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.03 during trading on Thursday, reaching $16.27. 7,838,256 shares of the company were exchanged, compared to its average volume of 9,413,924. The company has a market capitalization of $18.44 billion, a price-to-earnings ratio of -11.22, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company has a 50-day moving average of $17.99 and a two-hundred day moving average of $18.25. Teva Pharmaceutical Industries Limited has a twelve month low of $12.51 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares of the company's stock, valued at $15,296,950. The trade was a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.55% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.